NCT01416571View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 12, 2011

Primary Completion Date

November 29, 2011

Study Completion Date

September 28, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

Intramuscular (IM), two doses

Trial Locations (1)

85213

GSK Investigational Site, Mesa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY